
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has received approval for Filspari, increasing the probability of success for the FSGS indication to 100%, leading to a revised DCF-derived valuation estimate. The addressable treatment population for Filspari has expanded to over 30,000 patients in FSGS, reflecting significant growth potential in tandem with a projected revenue increase from ~$2 million quarterly to ~$26 million by Q4 2026, supported by an anticipated faster initial ramp-up due to existing commercial infrastructure from the IgAN launch. Management estimates that with the combined addressable patients across FSGS and IgAN exceeding 100,000, peak sales potential could exceed $3 billion annually, bolstering the long-term growth outlook for the company.
Bears say
Travere Therapeutics Inc faces significant risks that could hinder its financial performance and negatively impact its stock outlook. Potential delays or failures in the commercialization of its products, such as Filspari and pegtibatinase, may reduce sales potential and affect the company's overall valuation. Additionally, challenges in securing necessary funding for clinical trials and product development, coupled with the possibility of market access constraints, pose further threats to Travere's ability to execute its business strategy effectively.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares